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Activation of synovial fibroblasts in rheumatoid arthritis:
lack of expression of the tumour suppressor PTEN at sites
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Statement of findings
In the present study, we searched for mutant PTEN transcripts in aggressive rheumatoid
arthritis synovial fibroblasts (RA-SF) and studied the expression of PTEN in RA. By
automated sequencing, no evidence for the presence of mutant PTEN transcripts was
found. However, in situ hybridization on RA synovium revealed a distinct expression pattern
of PTEN, with negligible staining in the lining layer but abundant expression in the sublining.
Normal synovial tissue exhibited homogeneous staining for PTEN. In cultured RA-SF, only
40% expressed PTEN. Co-implantation of RA-SF and normal human cartilage into severe
combined immunodeficiency (SCID) mice showed only limited expression of PTEN, with no
staining in those cells aggressively invading the cartilage. Although PTEN is not genetically
altered in RA, these findings suggest that a lack of PTEN expression may constitute a
characteristic feature of activated RA-SF in the lining, and may thereby contribute to the
invasive behaviour of RA-SF by maintaining their aggressive phenotype at sites of cartilage
destruction.
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MMP = matrix metalloproteinase; M-MuLV = Moloney murine leukemia virus; PCR = polymerase chain reaction; Pfu = Pyrococcus furiosis; RA = rheuma-
toid arthritis; SCID = severe combined immunodeficiency; SDS = sodium dodecyl sulphate; SF = synovial fibroblast; TGF = transforming growth factor.
Aims: PTEN is a novel tumour suppressor which exhibits
tyrosine phosphatase activity as well as homology to the
cytoskeletal proteins tensin and auxilin. Mutations of PTEN have
been described in several human cancers and associated with
their invasiveness and metastatic properties. Although not
malignant, rheumatoid arthritis synovial fibroblasts (RA-SF)
exhibit certain tumour-like features such as attachment to
cartilage and invasive growth. In the present study, we analyzed
whether mutant transcripts of PTEN were present in RA-SF. In
addition, we used in situ hybridization to study the expression of
PTEN messenger (m)RNA in tissue samples of RA and normal
individuals as well as in cultured RA-SF and in the severe
combined immunodeficiency (SCID) mouse model of RA.
Methods: Synovial tissue specimens were obtained from
seven patients with RA and from two nonarthritic individuals.
Total RNA was isolated from synovial fibroblasts and after first
strand complementary (c)DNA synthesis, polymerase chain
reaction (PCR) was performed to amplify a 1063 base pair
PTEN fragment that encompassed the coding sequence of
PTEN including the phosphatase domain and all mutation sites
described so far. The PCR products were subcloned in
Escherichia coli, and up to four clones were picked from each
http://arthritis-research.com/content/2/1/059
Arthritis Research    Vol 2 No 1 Pap et al
plate for automated sequencing. For in situ hybridization,
digoxigenin-labelled PTEN-specific RNA probes were
generated by in vitro transcription. For control in situ
hybridization, a matrix metalloproteinase (MMP)-2-specific
probe was prepared. To investigate the expression of PTEN in
the absence of human macrophage or lymphocyte derived
factors, we implanted RA-SF from three patients together with
normal human cartilage under the renal capsule of SCID mice.
After 60 days, mice were sacrificed, the implants removed and
embedded into paraffin.
Results: PCR revealed the presence of the expected 1063
base pair PTEN fragment in all (9/9) cell cultures (Fig. 1). No
additional bands that could account for mutant PTEN variants
were detected. Sequence analysis revealed 100% homology of
all RA-derived PTEN fragments to those from normal SF as well
as to the published GenBank sequence (accession number
U93051). However, in situ hybridization demonstrated
considerable differences in the expression of PTEN mRNA
within the lining and the sublining layers of RA synovial
membranes. As shown in Figure 2a, no staining was observed
within the lining layer which has been demonstrated to mediate
degradation of cartilage and bone in RA. In contrast, abundant
expression of PTEN mRNA was found in the sublining of all RA
synovial tissues (Figs 2a and b). Normal synovial specimens
showed homogeneous staining for PTEN within the thin
synovial membrane (Fig. 2c). In situ hybridization using the
sense probe gave no specific staining (Fig. 2d). We also
performed in situ hybridization on four of the seven cultured
RA-SF and followed one cell line from the first to the sixth
passage. Interestingly, only 40% of cultured RA-SF expressed
PTEN mRNA (Fig. 3a), and the proportion of PTEN expressing
cells did not change throughout the passages. In contrast,
control experiments using a specific RNA probe for MMP-2
revealed mRNA expression by nearly all cultured cells (Fig. 3b).
As seen before, implantation of RA-SF into the SCID mice
showed considerable cartilage degradation. Interestingly, only
negligible PTEN expression was found in those RA-SF
aggressively invading the cartilage (Fig. 3c). In situ
hybridization for MMP-2 showed abundant staining in these
cells (Fig. 3d).
Discussion: Although this study found no evidence for
mutations of PTEN in RA synovium, the observation that PTEN
expression is lacking in the lining layer of RA synovium as well
Figure 1
Analysis of the amplified polymerase chain reaction products by
electrophoresis on a 1% agarose gel. The expected PTEN band was
visible in all normal (N1, N2 in lanes 3 and 4) and rheumatoid arthritis
(R1–R7 in lanes 6–12) specimens, and no additional transcripts could
be detected, even at lower specificity.
Figure 2
In situ hybridization on rheumatoid arthritis synovial tissue shows only
negligible expression of PTEN in the lining layer (A) but abundant
expression in the sublining layer (A, B). Normal synovium consisting of
only two to three cell layers of synovial cells showed clear staining,
both in the most superficial layers and in deeper regions (C). The
sense probe gave no specific staining (D).
Figure 3
In cultured rheumatoid arthritis synovial fibroblasts (RA-SF) only about
40% expressed PTEN (A) whereas matrix metalloproteinase (MMP)-2
was expressed constitutively by almost every cell (B). PTEN expression
(C) was negligible in RA-SF aggressively invading the co-implanted
cartilage in the renal capsule of severe combined immunodeficiency




as in more than half of cultured RA-SF is of interest. It suggests
that loss of PTEN function may not exclusively be caused by
genetic alterations, yet at the same time links the low
expression of PTEN to a phenotype of cells that have been
shown to invade cartilage aggressively.
It has been proposed that the tyrosine phosphatase activity of
PTEN is responsible for its tumour suppressor activity by
counteracting the actions of protein tyrosine kinases. As some
studies have demonstrated an upregulation of tyrosine kinase
activity in RA synovial cells, it might be speculated that the lack
of PTEN expression in aggressive RA-SF contributes to the
imbalance of tyrosine kinases and phosphatases in this
disease. However, the extensive amino-terminal homology of
the predicted protein to the cytoskeletal proteins tensin and
auxilin suggests a complex regulatory function involving cellular
adhesion molecules and phosphatase-mediated signalling. The
tyrosine phosphatase TEP1 has been shown to be identical to
the protein encoded by PTEN, and gene transcription of TEP1
has been demonstrated to be downregulated by transforming
growth factor (TGF)-β. Therefore, it could be hypothesized that
TGF-β might be responsible for the downregulation of PTEN.
However, the expression of TGF-β is not restricted to the lining
but found throughout the synovial tissue in RA. Moreover, in our
study the percentage of PTEN expressing RA-SF remained
stable for six passages in culture, whereas molecules that are
cytokine-regulated in vivo frequently change their expression
levels when cultured over several passages. Also, cultured RA-
SF that were implanted into SCID mice and deeply invaded the
cartilage did not show significant expression of PTEN after 60
days. The drop in the percentage of PTEN expressing cells
from the original cell cultures to the SCID mouse implants is of
interest as this observation goes along with data from previous
studies that have shown the prominent expression of activation-
related molecules in the SCID mice implants that in vivo are
found predominantly in the lining layer. Therefore, our data
point to endogenous mechanisms rather than to the influence
of exogenous human cytokines or factors in the downregulation
of PTEN. Low expression of PTEN may belong to the features
that distinguish between the activated phenotype of RA-SF and
the sublining, proliferating but nondestructive cells.
Introduction
PTEN is a novel tumour suppressor that exhibits tyrosine
phosphatase activity as well as homology to the cytoskele-
tal proteins tensin and auxilin [1,2]. Mutations in PTEN
have been described in several human cancers, and have
been associated with the invasiveness and metastatic
properties of malignancies [1–3]. Although not malignant,
rheumatoid arthritis (RA) synovial fibroblasts (SF) are
imbued with certain tumour-like features such as attach-
ment to cartilage and invasive growth [4]. Moreover, it has
been suggested that tyrosine kinase activity, which coun-
teracts the action of tyrosine phosphatases, is increased
in RA [5] and may be involved in the activation of mitogen-
activated protein kinase in human synovial cells [6].
In the present study, we analyzed whether mutant transcripts
of PTEN were present in RA-SF. In addition, we studied the
expression of PTEN messenger (m)RNA in tissue samples
from seven RA patients and two normal individuals, as well
as in cultured RA-SF and in the severe combined immuno-
deficiency (SCID) mouse co-implantation model of RA.
Aggressively invading RA-SF expressed only low levels of
PTEN, which showed no evidence for mutations. This lack of
expression was maintained in cultured RA-SF over several
passages, and when RA-SF were implanted into SCID mice
together with normal human cartilage.
Methods
Tissue preparation and cell cultures
Synovial tissue specimens were obtained from seven
patients with RA undergoing synovectomy or joint replace-
ment and from two nonarthritic individuals. Immediately
after surgery, one part of the tissue was embedded in
Tissue-Tek OCT medium (Miles, Elkhart, IN, USA), snap-
frozen and stored at –80°C, and a second was fixed in 4%
buffered formalin for 6 h before embedding in paraffin.
Another portion was digested enzymatically and the
released cells were grown in Dulbecco’s modified Eagle
medium with 10% foetal calf serum [7]. At confluence,
cells were harvested and half of them were used for com-
plementary (c)DNA preparation. The remaining cells were
used to maintain the culture, as well as for growing cells
on chamber slides (Lab-Tek II; Nalge Nunc Int, Naperville,
IL, USA) 48 h before in situ hybridization.
RNA isolation and reverse transcription polymerase chain
reaction
Total RNA was isolated from cultured SA applying the
TRIzol RNA isolation kit (Life Technologies, Basel, Switzer-
land) according to the manufacturer’s protocol. After first
strand cDNA synthesis using oligo-d(T)12–18 primers and
Moloney murine leukemia virus (M-MuLV) reverse tran-
scriptase (Boehringer-Mannheim, La Jolla, California,
USA), a 1063 base pair PTEN cDNA fragment was ampli-
fied using polymerase chain reaction (PCR) with Pyrococ-
cus furiosus (Pfu) DNA-polymerase (Stratagene, La Jolla,
California, USA). This fragment encompassed the coding
sequence of PTEN including the phosphatase domain and
all mutation sites described so far [1,8–10]. The primer
sequences were as follows: upper primer 5′-GAC AGC
CAT CAT CAA AGA GA-3′; and lower primer, 5′-TGA
CGG CTC CTC TAC TGT T-3′. The amplification was
carried out for 32 cycles under annealing–extension con-
ditions of 52°C for 1 min and 72°C for 2 min using a
Perkin-Elmer (Foster City, California, USA) DNA-Thermo-
cycler 480. To look for additional, low copy transcripts, the
cycle number was increased stepwise up to 42 cycles
and the annealing temperature was decreased to 48°C.
Cloning and sequencing of the PTEN fragments
The PCR products were then ligated into the PCR-Script
Amp SK+ vector (Stratagene), and transformation of the
vector into Epicurian Coli XL1-Blue MRF′ Kan supercom-
petent cells was performed. After selection, up to four
clones were picked from each plate and plasmid prepara-
tion of the PTEN-insert containing plasmids was per-
formed using the Qiagen MiniPrep Kit (Qiagen, Basel,
Switzerland). The sequences of the inserts were deter-
mined using automated, dideoxy sequencing.
Riboprobe preparation
The Qiagen MaxiPrep Kit was used for large scale prepara-
tion of PTEN-insert containing plasmids from two success-
fully transfected clones, and templates were prepared by
linearization with BamH I or Not I (Life Technologies).
Again, plasmid sequence was checked by automated
sequencing, which confirmed the 100% identity of the
PTEN fragment to the published GenBank sequence
(accession number 193051). Antisense and sense RNA
probes were then obtained by in vitro transcription using
T3 and T7 RNA polymerase (Boehringer-Mannheim) with a
commercially available transcription kit (Stratagene). For in
situ hybridization, probes were labelled with digoxigenin-
UTP (Boehringer-Mannheim). The RNA probe for control in
situ hybridization to detect matrix metalloproteinase (MMP)-
2 was prepared accordingly using a plasmid obtained from
the American Type Culture Collection (ATCC, Rockville,
Maryland, USA; ATCC number 79066).
In situ hybridization
In situ hybridization was performed as described by
Kriegsmann et al [11]. Briefly, after fixation, tissue sections
were hybridized with the digoxigenin-labelled riboprobes
(either antisense or sense) in hybridization buffer contain-
ing 50% formamide, 1× Denhardt’s solution, 10% dextran
sulphate, 25 µg/ml herring sperm DNA (Boehringer-
Mannheim), 40 mg/ml yeast transfer RNA (Sigma Chemi-
cal Co, St Louis, Missouri, USA) for 16 h at 52°C. After
hybridization, unbound probe was digested at 37°C for
45 min with 10 µg/ml RNase A (Boehringer-Mannheim),
and consecutive washing steps were performed at 50°C
at the following stringencies: 50% formamide/2 × SSC
(5 min); 1 × SSC + 1% sodium dodecyl sulphate (SDS;
15 min); 0.25 × SSC + 1% SDS (15 min); and 0.1%
SSC + 1% SDS (15 min). Immunological detection was
performed after blocking nonspecific binding sites with
2% horse serum (30 min at room temperature) by incuba-
tion with alkaline phosphatase-conjugated antidigoxigenin
Fab fragments (Boehringer-Mannheim) for 1 h at room
temperature, diluted 1/500 in Tris-NaCl, pH 7.6, contain-
ing 1% normal horse serum. After washing with Tris-NaCl
(pH 7.6) and Tris-NaCl/MgCl2 (pH 9.5), the sections were
incubated with 5-bromo-4-chloro-3-indolyl-phosphate/4-
nitro blue tetrazolium chloride colour substrate solution
(Boehringer Mannheim) containing 1 mmol/l levamisole
(DAKO, Zug, Switzerland), and developed at room tem-
perature in darkness. Colour development was stopped
with Tris-NaCl (pH 7.6).
Severe combined immunodeficiency mouse co-implantation
experiments
SCID mice were obtained from the Charles Rivers GmbH
(Sulzfeld, Germany) and kept permanently in sterile condi-
tions. Implantation of RA-SF together with normal human
cartilage was performed as described previously [7]. RA-
SF from three different patients were used for the SCID
mouse experiments. Briefly, after trypsinization, washing
and centrifugation, 105 cells were resuspended in 100 µl
sterile culture medium and inserted into the cavity of an
inert sponge (Gelfoam, Pharmacia & Upjohn, Dübendorf,
Germany) together with an 1 mm3 piece of normal human
articular cartilage. Mice were anaesthetized intraperi-
toneally with 0.014 mg/g Xylocain (Lidocain hydrochlo-
ride; Astra Pharmaceutica, Dieticon, Switzerland) and
0.09 mg/g Ketalar (Ketamin hydrochloride; Parke-Davis,
Baar, Switzerland) in an isotonic solution, and a 1 cm inci-
sion was made on the left flank of the animals. The left
kidney was exteriorized and, once a small incision was
made, an implant was placed under the renal capsule. The
peritoneal layer and the skin were closed using 5.0
prolene suture material. After 60 days, mice were sacri-
ficed and the implants removed. Tissue preparation
included fixation in 4% buffered formalin and paraffin
embedding according to standard procedures.
Results
Using the specific primers, the expected 1063 base pair
PTEN fragment was amplified from the total cDNA of all
(all of nine) cell cultures by PCR. Moreover, no additional
bands that could account for mutant PTEN variants were
detected, even when PCR conditions were changed
towards lower specificity (Fig. 1). PCR products were
then subcloned into Escherichia coli, and up to four suc-
cessfully transformed clones were picked for plasmid
preparation from each culture plate (total number of
samples 21). Sequence analysis revealed 100% homo-
logy of all RA-derived PTEN fragments to those obtained
from normal SF as well as to the published GenBank
sequence (accession number U93051).
In situ hybridization with digoxigenin-labelled RNA probes,
however, demonstrated considerable differences in the
expression of PTEN mRNA within the lining and the sublining
layers of RA synovial membranes. As shown in Figure 2a, no
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staining was observed within the lining layer, which has been
demonstrated to mediate degradation of cartilage and bone
in RA [4]. In contrast, abundant expression of PTEN mRNA
was found in the sublining layer of all RA synovial tissues
(Figs 2a and b). Normal synovial specimens showed homo-
geneous staining for PTEN within the thin synovial mem-
brane (Fig. 2c). Expression of PTEN mRNA was seen in the
most superficial layer of normal synovium as well as in
deeper regions, with most cells being of fibroblast shape
(Fig. 2c). In situ hybridization using the sense probe gave no
specific staining (Fig. 2d). We also performed in situ
hybridization on four of the seven cultured RA-SF and fol-
lowed one cell line from the first to the sixth passage. Inter-
estingly, only 40% of cultured RA-SF expressed PTEN
mRNA (Fig. 3a), and the proportion of PTEN-expressing cells
did not change significantly throughout the passages. In con-
trast, control experiments using a specific RNA probe for
MMP-2 revealed mRNA expression by nearly all cultured
cells (Fig. 3b) indicating constitutive expression of MMP-2
but not of PTEN in the absence of macrophages and lym-
phocytes, and their locally derived factors.
To test the hypothesis further that PTEN downregulation
in RA-SF is not caused by such exogenous factors, we co-
implanted RA-SF from three patients together with normal
human cartilage under the renal capsule of SCID mice and
maintained the implants for 60 days as described previ-
ously [7]. Before implantation, RA-SF showed the above
described expression pattern for PTEN. Histological evalu-
ation of the implants after the rats were killed revealed
considerable cartilage degradation by the RA-SF [7].
Interestingly, by in situ hybridization with PTEN-specific
RNA probes, only negligible PTEN expression was found
in those RA-SF aggressively invading the cartilage
(Fig. 3c). Again, control in situ hybridization with RNA
probes for MMP-2 showed abundant staining in these
cells (Fig. 3d).
Discussion
Although the present study found no evidence for muta-
tions of PTEN in RA synovium, the observation that PTEN
expression is lacking in the lining layer of RA synovium as
well as in more than half of cultured RA-SF is of interest.
This suggests that loss of PTEN function may not exclu-
sively be caused by genetic alterations, but that it links the
low expression of PTEN to a phenotype of cells that have
been shown to invade cartilage aggressively. Moreover,
the present results may also have an impact on further
investigations of other tumour suppressors such as p53,
which has been found to be genetically altered simultane-
ously with PTEN in several cancers [10], and somatic
mutations of which have also been described in RA [12].
On the basis of the inconsistency and great variability of
p53 mutations in RA, it has been proposed that these
mutations, although contributing to the invasive behaviour
of rheumatoid tissue, may occur secondary to other
changes and may not represent the primary step in the
activation of RA-SF [12]. These data, together with our
observations of PTEN downregulation in nonmalignant but
aggressively invading RA-SF, suggest that the lack of
PTEN expression may be specifically associated with
certain features of malignant cells.
It has been proposed that the tyrosine phosphatase activity
of PTEN is responsible for its tumour suppressor activity
[1,13] by counteracting the actions of protein tyrosine
kinases. Because some studies have demonstrated an
upregulation of tyrosine kinase activity in RA synovial cells,
it might be speculated that the lack of PTEN expression in
aggressive RA-SF contributes to the imbalance of tyrosine
kinases and phosphatases in this disease [5]. The exten-
sive amino-terminal homology of the predicted protein to
the cytoskeletal proteins tensin and auxilin, however, sug-
gests a complex regulatory function involving cellular adhe-
sion molecules and phosphatase-mediated signalling [9].
Tamura et al [13] most recently demonstrated that PTEN
interacts with the focal adhesion kinase, and negatively
regulates cellular interactions with the extracellular matrix
by inhibiting integrin-mediated cell spreading, as well as
formation of focal adhesions. Also, the tyrosine phos-
phatase TEP1 has been shown to be identical to the
protein encoded by PTEN, and gene transcription of TEP1
has been demonstrated to be downregulated by trans-
forming growth factor (TGF)-β [14]. Therefore, it could be
hypothesized that TGF-β, which is expressed abundantly
in the RA synovial membrane [15], might be responsible
for the downregulation of PTEN. The expression of TGF-β
is not restricted to the lining, however, but is found
throughout the synovial tissue in RA [15]. Moreover, in the
present study the percentage of PTEN-expressing RA-SF
remained stable for six passages in culture, whereas mole-
cules that are cytokine-regulated in vivo frequently change
their expression levels when cultured over several pas-
sages. Also, cultured RA-SF that were implanted into
SCID mice and deeply invaded the cartilage did not show
significant expression of PTEN after 60 days.
The drop in the percentage of PTEN-expressing cells from
the original cell cultures to the SCID mouse implants is of
interest, because this observation is in accord with data
from previous studies [16] that showed the prominent
expression of activation related molecules in the SCID
mice implants that are found predominantly in the lining
layer in vivo. It may be speculated that activated, aggres-
sive RA-SF are selected positively during the implantation
by apoptosis of the nonaggressive cells.
With regard to PTEN, the present data point to endoge-
nous mechanisms rather than to the influence of exoge-
nous human cytokines or factors in the downregulation of
PTEN. In this context, the question of whether the PTEN
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low-expressing phenotype constitutes a subset of RA-SF
that are identical to previously described activated RA-SF
is of critical importance. Some recent studies [16] search-
ing for apoptosis regulating molecules as well as adhesion
molecules and signalling cascades in RA-SF have pro-
vided novel insights into the nature of these aggressive
RA-SF and have helped to characterize them on a molecu-
lar level. Thus far, though, there is no specific marker for
the activated phenotype of RA-SF found in the lining layer
of RA patients. Low expression of PTEN may be among
the features that distinguish between the activated pheno-
type of RA-SF and the sublining, proliferating but nonde-
structive cells. It needs to be stressed, however, that the
association between the lack of PTEN expression and the
aggressive phenotype of RA-SF is, at this point, only phe-
nomenological. A comprehensive analysis of different
markers and pathways including functional analysis will be
needed to clearly identify and specifically distinguish the
activated phenotype of RA-SF that aggressively invade the
cartilage in RA on a molecular level.
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